Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Context: The effect of glycemic control on persisting albuminuria remains unclear. Insulin delivery and glucose variability may be important. Objective: This study aimed to investigate the effect of 1-year treatment with sensor-augmented insulin pump (SAP) or multiple daily injections (MDIs) on albuminuria. Design, Patients, and Methods: This was a randomized controlled open-label parallel trial composed of 60 patients with type 1 diabetes with a history of albuminuria and on stable renin-angiotensin system inhibition, were randomly assigned to SAP or MDI. Urine albumin creatinine ratio (UACR) was measured in three urine samples at all visits. Glucose variability and glomerular filtration rate (51Cr-EDTA-GFR) were measured at beginning and study end. Using linear mixed model, change in UACR between groups was analyzed as intention to treat. Main Outcome Measure: Change in UACR was measured. Results: Fifty-five patients (SAP, n = 26; MDI, n = 29) completed the study. Diabetes duration (mean ± SD, 33 ± 12 y), UACR (geometric mean, 99 mg/g; interquartile range, 37–233 mg/g), 51Cr-EDTA-GFR (94 ± 22 mL/min/1.73m2), glycosylated hemoglobin (HbA1c) (9.0 ± 1.1%), glucose variability (calculated as SD), 4.0 ± 1.0 mmol/l; no-group differences (P ≥ .06 for all). After 1 year, change in UACR was mean, −13%; 95% confidence interval, −39 to 22 with SAP vs mean, 30%; 95% CI, −12 to 92% on MDI treatment (unadjusted P = .051; adjusted for HbA1c, P = .04). HbA1c decreased 1.3 ± 1.0 vs 0.6 ± 1.0% (P = .013), glucose variability decreased 0.9 ± 1.1 vs 0.3 ± 1.0 mmol/L (P = .04), and 51Cr-EDTA-GFR declined 5.6 ± 9.6 vs 3.4 ± 13 mL/min/1.73m2 (P = .50) with SAP vs MDI treatment. There were no changes in blood pressure (P ≥ .27). Conclusion: SAP treatment reduced UACR in a randomized controlled trial in type 1 diabetes patients with a history of albuminuria on stable renin-angiotensin system inhibition. Significance was reached after adjustment. SAP treatment reduced HbA1c and glucose variability (calculated as SD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A 3.38-fold increased risk of DKA (often euglycemic, now generally defined as a BG less than 250 mg/dL)1179 has resulted in no approval in the United States, although the European Medicine Agency has approved dapagliflozin (5 mg) and sotagliflozin (200 mg) for those with T1D and a BMI above 27 kg/m2.1180”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1180]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202 · cited 6×
“First Published Online September 21, 2015 Abbreviations: 51Cr-EDTA-GFR, glomerular filtration rate; BMI, body mass index; BP, blood pressure; CGM, continuous glucose monitoring; CI, confidence interval; CSII, continuous subcutaneous insulin infusion; DCCT, Diabetes Control and Complications Trial; ESRD, end-stage rena…”
BackgroundInfluentialEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 1×
“In addition, a large randomized controlled study comparing sensor augmented insulin pump (SAP) treatment with MDI showed a significant reduction in HbA1c in the SAP- vs MDI-treated patients (10).”
Backgroundde Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Circulation · doi:10.1161/01.cir.0000139860.33974.28 · Cited by 750 · cited 1×
“Also, in type 2 diabetes, a decrease in UAER is associated with a reduction of cardiovascular events independent of the level of albuminuria (20).”
BackgroundThe Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Pickup, J. C., & Sutton, A. J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02486.x · Cited by 617
Feldt-Rasmussen, B., Mathiesen, E., & Deckert, T. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91433-9 · Cited by 447 · cited 10×
“First Published Online September 21, 2015 Abbreviations: 51Cr-EDTA-GFR, glomerular filtration rate; BMI, body mass index; BP, blood pressure; CGM, continuous glucose monitoring; CI, confidence interval; CSII, continuous subcutaneous insulin infusion; DCCT, Diabetes Control and Complications Trial; ESRD, end-stage rena…”
BackgroundMethodInfluentialPredictors of mortality in insulin dependent diabetes: 10 year observational follow up study
Rossing, P., Hougaard, P., Borch-Johnsen, K., & Parving, H.-H. (1996) · BMJ · doi:10.1136/bmj.313.7060.779 · Cited by 428 · cited 1×
“Patients with micro- or macroalbuminuria have an increased risk of cardiovascular and all-cause mortality compared with normoalbuminuria (17, 18).”
BackgroundSelf-citationUS Renal Data System 2012 Annual Data Report
Collins, A. J., Foley, R. N., Herzog, C., Chavers, B., Gilbertson, D., Herzog, C., Ishani, A., Johansen, K., Kasiske, B., Kutner, N., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.031 · Cited by 425 · cited 1×
“However, diabetic nephropathy is still the leading cause of end-stage renal disease (ESRD) in Europe and the United States (3, 4), and additional interventions are needed.”
BackgroundMisso, M. L., Egberts, K. J., Page, M., O'Connor, D., & Shaw, J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005103.pub2 · Cited by 406 · cited 1×
“In a systematic review, treatment with continuous subcutaneous insulin infusion (CSII) was documented to lower HbA1c (glycosylated hemoglobin) significantly without increasing hypoglycemic events compared with multiple daily injections (MDI) (9).”
BackgroundHill, N. R., Oliver, N. S., Choudhary, P., Levy, J. C., Hindmarsh, P., & Matthews, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0247 · Cited by 362 · cited 1×
“uk/research/diabetes/software/ easygv) (15).”
Rossing, P., Hommel, E., Smidt, U. M., & Parving, H. H. (1994) · Diabetologia · doi:10.1007/s001250050140 · Cited by 192 · cited 1×
“In a study of 18 patients with type 1 diabetes and nephropathy a reduction in albuminuria after 1 year of treatment with RAS inhibition was significantly correlated with a smaller decline in (51)Cr-GFR whereas reduction in BP was not (21).”
BackgroundSelf-citationMicroalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga
Bakris, G. L., & Molitch, M. (2014) · Diabetes Care · doi:10.2337/dc13-1870 · Cited by 186 · cited 1×
“Patients with micro- or macroalbuminuria have an increased risk of cardiovascular and all-cause mortality compared with normoalbuminuria (17, 18).”
Background(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183 · cited 1×
“Intensive glycemic control is effective in preventing development of micro and macro albuminuria in normoalbuminuric patients with type 1 diabetes (1).”
BackgroundChoudhary, P., Ramasamy, S., Green, L., Gallen, G., Pender, S., Brackenridge, A., Amiel, S. A., & Pickup, J. C. (2013) · Diabetes Care · doi:10.2337/dc13-0939 · Cited by 160
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2009) · Diabetes Care · doi:10.2337/dc09-0109 · Cited by 144 · cited 1×
“of future diabetes complications (26), whereas, a smaller cross-sectional study including 32 patients showed higher glucose variability (expressed as SD and MAGE) in patients with presence of microvascular complications at”
BackgroundŠoupal, J., Škrha, J., Fajmon, M., Horová, E., Mráz, M., Škrha, J., & Prázný, M. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0205 · Cited by 120
Feldt-Rasmussen, B., Mathiesen, E. R., Hegedüs, L., & Deckert, T. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603133141101 · Cited by 111 · cited 1×
“Feldt-Rasmussen et al (5) revealed a significant reduction in albuminuria in 18 patients after treatment with CSII for 2 years compared with 18 patients treated with 1–2 daily injections, but not after the first year (16).”
BackgroundHeinemann, L., Fleming, G. A., Petrie, J. R., Holl, R. W., Bergenstal, R. M., & Peters, A. L. (2015) · Diabetologia · doi:10.1007/s00125-015-3513-z · Cited by 87
The Challenges of Measuring Glycemic Variability
Rodbard, D. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600328 · Cited by 84 · cited 1×
“Assessment of glucose variability poses several challenges, including limited stability and reliability of the CGM and the ambiguity of which measure is best and most reproducible (25).”
BackgroundImproved prognosis of diabetic nephropathy in type 1 diabetes
Andrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H., Hovind, P. H., Hansen, T. W., & Rossing, P. R. (2014) · Kidney International · doi:10.1038/ki.2014.206 · Cited by 75
Self-citationon behalf of the ONTARGET/TRANSCEND investigators, Schmieder, R. E., Schutte, R., Schumacher, H., Böhm, M., Mancia, G., Weber, M. A., McQueen, M., Teo, K. K., & Yusuf, S. (2014) · Diabetologia · doi:10.1007/s00125-014-3330-9 · Cited by 51 · cited 1×
“A recent analysis, comprising almost 23 000 subjects with type 1 and type 2 diabetic and nondiabetic included in the ONTARGET and TRANSCEND studies showed a decrease albuminuria during 2 years was associated with lower risk of cardiovascular event and mortality compared with an increase in albuminuria (19).”
BackgroundSavarese, G., Dei, A., Rosano, G. M. C., D’Amore, C., Musella, F., Mosca, S., Reiner, M. F., Marchioli, R., Trimarco, B., & Filardi, P. P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.01.065 · Cited by 50 · cited 1×
“A recent meta-analysis comprising 80 000 patients with diabetes found a 10% reduction in UAER corresponded to a 13% reduction in MI, 29% reduction in stroke, and 14% reduction in the composite endpoint of cardiovascular death, stroke, and MI (22).”
MethodAssessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis
Jun, M., Turin, T. C., Woodward, M., Perkovic, V., Lambers Heerspink, H. J., Manns, B. J., Tonelli, M., & Hemmelgarn, B. R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040396 · Cited by 45 · cited 1×
“However, a recent metaanalysis showed evidence of albuminuria performing well as a proxy of ESRD even though it still needs further assessment (23).”
BackgroundBuse, J. B., Kudva, Y. C., Battelino, T., Davis, S. N., Shin, J., & Welsh, J. B. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0294 · Cited by 41 · cited 5×
“2015-2839 J Clin Endocrinol Metab, November 2015, 100(11):4181–4188 press.”
BackgroundInfluentialThe extracellular fluid volume in normal man determined as the distribution volume of [51Cr] EDTA
Brøchner‐Mortensen, J. (1982) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365518209168083 · Cited by 24 · cited 1×
“GFR was measured at baseline and end of study using an isotopic plasma clearance method with (51)Cr-EDTA according to local guidelines, with a day-to-day coefficient of variation of 4% (14).”
MethodLepore, G., Bruttomesso, D., Bonomo, M., Dodesini, A. R., Costa, S., Meneghini, E., Corsi, A. M., Nosari, I., & Trevisan, R. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02736.x · Cited by 17 · cited 1×
“Furthermore, in 2009 in an observational study, Lepore et al (12) showed a decrease in urine albumin creatinine ratio (UACR) in patients with microalbuminuria after initiation of CSII (n 19) compared with MDI treatment (n 19), but could not demonstrate an association between this decrease in UACR and CSII treatment af…”
MethodChimenti, E. M., de la Morena, L. H., Vaquero, P. M., de Ibarra, L. S., Domínguez, M. G., & Sánchez, L. F. P. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.016 · Cited by 11 · cited 2×
“This is in line with results from Chimenti et al (24), who found SD of glucose variability assess from blinded CGM to decrease from 3.2 to 2.8 mmol/l over 2 months when patients changed from MDI to CSII treatment.”
ResultInfluential
Research works printed but not linked: 1
- Rosenlund, Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c as compared to multiple daily injections: a longitudinal follow-up study [published online October 6, 2015], Diabet Med
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Karges, B., Schwandt, A., Heidtmann, B., Kordonouri, O., Binder, E., Schierloh, U., Boettcher, C., Kapellen, T., Rosenbauer, J., & Holl, R. W. (2017) · JAMA · doi:10.1001/jama.2017.13994 · Cited by 452
Benkhadra, K., Alahdab, F., Tamhane, S. U., McCoy, R. G., Prokop, L. J., & Murad, M. H. (2017) · Endocrine · doi:10.1007/s12020-016-1039-x · Cited by 113
Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S., & Nørgaard, K. (2020) · Diabetes Care · doi:10.2337/dc20-0909 · Cited by 72
Self-citationGoing beyond HbA1c to understand the benefits of advanced diabetes therapies
Vigersky, R. A. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12846 · Cited by 42
Metadata
- Authors
- Rosenlund, S., Hansen, T. W., Rossing, P., & Andersen, S.
- Affiliations
- Nordsjællands Hospital (DK)
- Steno Diabetes Center (S.R., T.W.H., P.R.), 2820 Gentofte, Denmark
- University of Copenhagen (DK)
- Corresponding author
- Rosenlund, Signe
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11-01
- Volume
- 100
- Issue
- 11
- Pages
- 4181-4188
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2103888042
- Cited by
- 19
- References
- 30
- Citations by year
- 2023: 3 · 2022: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 3
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.scopus.com
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- sensor-augmented pump, multiple daily insulin injections, albuminuria, type 1 diabetes, glycemic control, glycemic variability, glomerular filtration rate, albumin-creatinine ratio, renin-angiotensin system blockade, diabetic nephropathy, HbA1c, continuous glucose monitoring, insulin delivery method, glomerular hyperfiltration
- MeSH terms
- Adolescent, Adult, Aged, Albuminuria, Blood Glucose, Blood Pressure, Creatinine, Diabetes Mellitus, Type 1, Female, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Biosensing Techniques, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.